Two clinical trials of targeted therapies led by Memorial Sloan-Kettering investigators show promising results against different types of sarcoma.

Dr. Douer, leader of the research program in acute lymphoblastic leukemia, talks about how patients are treated by a caring team that includes physicians, nurses, social workers, and support staff.

Early research led by investigators at Memorial Sloan-Kettering cautions against combining ipilimumab and vemurafenib for the treatment of metastatic melanoma.

A study identifies genetic variations that alter the risk of breast cancer in women who have a certain gene mutation.

Memorial Sloan-Kettering researchers have used genetically modified immune cells to eradicate cancer in five patients with acute lymphoblastic leukemia.

At the seventh annual seminar for high school students and teachers, investigators discuss how cutting-edge biomedical research may ultimately contribute to better treatments for cancer patients.

Researchers have found that the investigational drug selumetinib shuts down the signaling of genetic mutations that prevent some patients’ thyroid cancer tumors from absorbing radioiodine, the most effective treatment for the disease.